Quest Diagnostics Inc (NYSE: DGX) has benefited from exceptional positive changes in investment behavior: positive upside/downside volume developed, the stock’s recent price rise disrupted its longer term downtrend, and the stock rose on very heavy volume.
Recent small positive changes in fundamentals have benefitted Quest Diagnostics Inc (NYSE: DGX): significant quarterly earnings acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
DGX is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Quest Diagnostics has a current Value Trend Rating of C (Low Neutral). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Quest Diagnostics has a neutral Appreciation Score of 54 and a slightly negative Power Rating of 39, resulting in the Low Neutral Value Trend Rating.
Recent Price Action
Quest Diagnostics Inc (NYSE: DGX) stock enjoyed a large increase of 3.9% on 4/29/24. The stock closed at $139.50. Moreover, this advance was accompanied by exceptionally high trading volume at 273% of normal. The stock has performed in line with the market over the last nine months and has risen 8.6% during the last week.
Be the first to comment